European Society of Human Reproduction and Embryology

COVID-19 information

ESHRE COVID-19 working group

In view of the rapidly growing number of reports and the impact of the COVID-19 coronavirus on public health, ESHRE has formed a specialist working group to keep track of bibliography and published scientific reports relevant to reproductive medicine, pregnancy and newborns.

The COVID-19 pandemic presents a unique global challenge on a scale not previously seen. The infectivity and mortality rates are higher than previous pandemics and the disease is present in almost every country. In this document, ASRM, ESHRE and the International Federation of Fertility Societies (IFFS) have come together to jointly affirm the importance for continued reproductive care during the COVID-19 pandemic.

As the COVID-19 pandemic is stabilising, the return to normal daily life will also see the need to restart the provison of ART treatments. Infertility is a disease and once the risk of SARS-CoV-2/COVID-19 infection is decreasing, all ART treatments can be restarted for any clinical indication, in line with local regulations.
However, vigilance and measured steps must be taken for safe practice and to minimise the risks related to SARS-CoV-2/COVID-19-positive patients or staff during treatment.
The ESHRE COVID-19 working group has prepared the “ESHRE Guidance on recommencing ART treatments”, a set of recommendations for centres planning to restart ART treatments.

Questions/Suggestions on COVID-19

Please e-mail us if you can't find an answer to your query. We aim to respond to your e-mail within two working days. We will respond to e-mails in the order in which they are received. Please note, our office hours are 9am-5pm (CET).

Has a COVID-19 infection been confirmed in one of your pregnant IVF patients? Please report the case to our platform. The anonymous information will be a piece in the puzzle and help us to answer critical questions with regards to the impact of COVID-19 on our patients.